This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

IntelGenx Secures Leadership Succession

SAINT LAURENT, Quebec, April 24, 2013 (GLOBE NEWSWIRE) -- Horst Zerbe, President and CEO of IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx" or the "Company") today announced that Rajiv Khosla RPh, PhD, MBA has been appointed Chief Operating Officer and Chief Scientific Officer of the Company, effective immediately. Dr. Khosla has been a member of the Company's board of directors for the past two years and, in accordance with the employment agreement, has now relinquished his board position.

"I am elated that Dr. Khosla has agreed to bring his outstanding leadership abilities and vision to IntelGenx on a full-time basis," Dr. Zerbe said, adding that the appointment is key to the Company's strategic plan for smooth succession, continuity and growth.

"We have secured the right leadership for the future," Dr. Zerbe said. "Rajiv has a record of success in business development and in leading growth in our sector. Those are essential attributes as IntelGenx moves forward."

Dr. Zerbe also noted that Dr. Khosla has deep knowledge in drug delivery systems. He is the first COO at IntelGenx. The succession plan will see Dr. Khosla become CEO and President of IntelGenx on January 1, 2014 and for Dr. Zerbe, who built the Company from the ground up, to remain as Chairman of the board of directors and continue to provide expertise in research and development, and manufacturing.

Since the beginning of this year, Dr. Khosla has been a consulting member of the IntelGenx management team, assisting with strategic operations, business development activities and advising on current and future pharmaceutical project development.

IntelGenx, a Canadian company, develops drug delivery systems that solve challenges encountered in oral drug delivery, with technologies that improve the performance of a wide variety of pharmaceutical compounds. IntelGenx has developed capacities to tailor drug release profiles and target specific absorption sites to unlock the full therapeutic potential of a drug. It recently submitted a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its anti-migraine oral film product, a novel oral thin-film formulation based on its proprietary VersaFilmâ„¢ technology

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs